AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
6min chapter
Episode #231: BMI Controversy and New Drug Breakthroughs
Barbell Medicine Podcast
Riptatritide: A New Drug for Obesity
The new drug, we think it's called Riptatritide or something like that. It is a glucagon, GIP, GLP1, triple agonist. There are three different sort of molecular targets for this drug formulation. Austin, you're going to take us through this phase two clinical trial that just got published. And so at the highest dose among the people who got up to the 12 milligram dose the average weight loss at 48 weeks was 24%.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode